Related Experiment Video

Updated: May 29, 2026

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

Targeting autophagy enhances BO-1051-induced apoptosis in human malignant glioma cells

Pei-Ming Chu1, Li-Hsin Chen, Ming-Teh Chen

  • 1Graduate Institutes of Life Sciences, National Defense Medical Center, Taipei, Taiwan, ROC.

Cancer Chemotherapy and Pharmacology
|September 28, 2011
PubMed
Abstract

Insights

BO-1051, a novel anticancer agent, effectively inhibits human glioma cell growth by inducing apoptosis and autophagy. Combining BO-1051 with autophagy inhibitors enhances its cytotoxic effects, offering a promising new treatment for malignant glioma.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • BO-1051 is an N-mustard derivative conjugated with DNA-affinic 9-anilinoacridine.
  • Previous studies indicated BO-1051 possesses potent anticancer activity.

Purpose of the Study:

  • To investigate the anti-glioma effects of BO-1051 in human glioma cell lines.
  • To elucidate the underlying mechanisms of BO-1051's action, including its impact on apoptosis and autophagy.

Main Methods:

  • Human glioma cell lines (U251MG, U87MG) were treated with BO-1051 alone or in combination with autophagic inhibitors.
  • Cell viability was assessed using MTT assays.
  • Apoptosis and autophagy induction were measured via flow cytometry, immunoblotting, acridine orange labeling, electron microscopy, and LC3 analysis.
  • RNA interference (shRNA) targeting Beclin1 was employed to study its role in apoptosis.

Main Results:

  • BO-1051 demonstrated dose-dependent suppression of viability in multiple glioma cell lines with significantly lower IC50 values compared to normal cells.
  • BO-1051 induced both apoptotic cell death and enhanced autophagic flux through Akt/mTOR inhibition and Erk1/2 activation.
  • Inhibition of autophagy using 3-methyladenine or bafilomycin A1, or Beclin1 knockdown, significantly potentiated BO-1051-induced apoptosis.

Conclusions:

  • BO-1051 triggers both apoptosis and autophagy in glioma cells.
  • Blocking autophagy amplifies the cytotoxic impact of BO-1051.
  • The combination of BO-1051 with autophagic inhibitors presents a potential novel therapeutic strategy for malignant glioma treatment.

More Related Videos

Cell-Based Drug Screening for Inhibitors of Autophagy Related 4B Cysteine Peptidase09:51

Cell-Based Drug Screening for Inhibitors of Autophagy Related 4B Cysteine Peptidase

Published on: June 30, 2023

Related Concept Videos

Autophagic Cell Death01:18

Autophagic Cell Death

Christian de Duve discovered “autophagy,” a process in which cellular components are engulfed by membrane-bound organelles called autophagosomes. The autophagosomes then fuse with lysosomes to digest the enclosed contents. Autophagy is generally activated in cells to prevent cell death. However, cell death is triggered when the damage is beyond repair.
Autophagy and Apoptosis
Autophagy can activate apoptosis. In normal conditions, the autophagy activating protein Beclin-1 and pro-apoptotic...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Autophagy01:27

Autophagy

Autophagy is a self-digesting process by which a cell protects itself from threats both within and outside the cell, ranging from abnormal proteins to invading bacteria. In this process, obsolete components of the cell and invading microbes are degraded by hydrolytic enzymes active in an acidic environment of the lysosomal lumen.
An autophagic pathway consists of a series of signaling events activated in response to diverse stress and physiological conditions such as food deprivation,...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...